— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.
— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.
— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.
— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.
— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.
— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.
— ACST shares gained 0.69% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Target (TGT): A look at some of the challenges faced by the retailer in 3Q24
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and
